Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study -- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and …

Vaxcyte is a clinical-stage vaccine innovation company based in San Carlos, California with the unique ability to rapidly engineer, optimize and manufacture superior, high-fidelity vaccines at …

Based on the body of positive evidence from the VAX-31 and VAX-24 adult Phase 1/2 programs, Vaxcyte believes its carrier-sparing platform has the potential to set a new standard in disease …

Feb 25, 2025 · Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is …

Working at Vaxcyte is about more than having a job – it’s about building your career as part of a special team committed to scaling beyond what’s possible. Read some of our employees’ …

At Vaxcyte, we are driven by our: Bold Goal To prevent or treat infections caused by bacterial diseases, such as invasive pneumococcal disease, Group A Strep, periodontitis and Shigella.

Conjugate vaccines induce a robust and boostable antibody response to the protective carbohydrate coating of Streptococcus pneumoniae.With VAX-31 and VAX-24, our potentially …

Mar 4, 2024 · Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter …

Vaxcyte Job Listings. Open Jobs. Filter By: Location Team. Employment Type. Work Arrangement. Clear Filters. Summer Intern, Procurement. San Carlos, California / Accounting …

Oct 19, 2023 · Vaxcyte expects to initiate the VAX-31 Phase 1/2 clinical study in adults in the fourth quarter of this year and announce topline safety, tolerability and immunogenicity results …